Cadrenal Therapeutics, Inc. (CVKD) company profile
Close on Nov 17, 2026Market cap $6.71MP/E –Yield 877.66%
About Cadrenal Therapeutics
Pharmaceutical Preparations, SIC 2834
Cadrenal Therapeutics, Inc. is a biopharmaceutical company that develops therapies for life-threatening immune and thrombotic conditions. Its lead drug candidate, CAD-1005, is a selective 12-lipoxygenase inhibitor evaluated for the treatment and prevention of heparin-induced thrombocytopenia. The company's pipeline also includes tecarfarin, an oral vitamin K antagonist intended for patients with end-stage kidney disease and atrial fibrillation or left ventricular assist devices, and frunexian, an intravenous Factor XIa inhibitor for acute hospital care. The company focuses on patient populations with complex anticoagulation requirements and high thrombotic risks.
The company is headquartered in Ponte Vedra, Florida, and is incorporated in Delaware. Operating primarily in the United States biopharmaceutical sector, its research scale includes clinical development programs that span Phase 1 through Phase 3 preparations, with candidate studies evaluating cohorts ranging from small patient groups to more than one thousand clinical subjects.
Summary of the business section of Cadrenal Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cadrenal Therapeutics, Inc.
- Headquarters
- Ponte Vedra, FL
- Address
- 822 A1a North, Suite 306 32082
- Phone
- (904) 300-0701
- Website
- cadrenal.com
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- CVKD
- Exchange
- Nasdaq
- IPO date
- Jan 23, 2023
- Shares outstanding
- 4M, Aug 13, 2026
- Public float
- $24.87M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-15 reverse, Aug 20, 2024
- SEC CIK
- 1937993
- CUSIP
- 127636207
- ISIN
- US1276362076
- FIGI
- BBG019STRT20
- Share class FIGI
- BBG019STRT39
- EIN
- 88-0860746
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Quang X. Pham | Chairman and CEO, Director | 298,589 |
| Jeffrey Scott Cole | Chief Operating Officer | – |
| Matthew K. Szot | Chief Financial Officer | 0 |
| James J. Ferguson III | Chief Medical Officer | – |
| Glynn Wilson | Director | 50,000 |
| Lee Scott Golden | Director | 1,667 |
| John Raymond Murphy | Director | 614,792 |
| Steven Zelenkofske | Director | 40,000 |
| Robert Lisicki | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Quang X. Pham Chief Executive Officer | $751.28K | $296.75K | $847.67K | $14.00K | $1.91M | +56% |
| Matthew Szot Former Chief Financial Officer | $459.72K | $181.59K | $652.05K | $13.67K | $1.31M | +51% |
| James J. Ferguson Former Chief Medical Officer | $457.41K | $136.35K | $778.92K | $23.13K | $1.40M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 23, 2023
- Offer price
- $5.00
- Securities offered
- 1,400,000
- Gross proceeds
- $7.00M
- Exchange
- Nasdaq
- First trading day
- Jan 20, 2023
- First-day close
- $4.12-17.6%
- Lock-up ends (est.)
- Jul 19, 2023
“We are offering 1,400,000 shares of our common stock, par value $0.001 per share (“common stock”), at the initial public offering price of $5.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 27, 2025, we had five employees, all of which are full-time, and engage approximately thirty-five consultants and contractors.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 5, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 5, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 15, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 8, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 23, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 17, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?